Copertina

Titration and discontinuation of semaglutide for weight management in commercially insured US adults

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yunwen Xu, Juan J. Carrero, Alexander R. Chang, Lesley A. Inker, Donglan Zhang, Amrita Mukhopadhyay, Saul B. Blecker, Leora I. Horwitz, Morgan E. Grams, Jung‐Im Shin
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Obesity
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity
di: Karan R. Chhabra, et al.
Pubblicazione: (2026)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
di: Lucas A. Mavromatis, et al.
Pubblicazione: (2025)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
di: Yunwen Xu, et al.
Pubblicazione: (2025)

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects
di: Malene Svoldgaard Sørensen, et al.
Pubblicazione: (2025)

Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study
di: Qoua L. Her, et al.
Pubblicazione: (2025)

Food insecurity and weight‐loss efforts among a nationally representative sample of US adults with higher weight
di: Kirstie M. Herb Neff
Pubblicazione: (2024)

The safety of semaglutide in patients with depression and obesity
di: Ziyi Yang, et al.
Pubblicazione: (2024)

Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy
di: Firas Bahdi, et al.
Pubblicazione: (2025)

Response to “The safety of semaglutide in patients with depression and obesity”
di: Robert F. Kushner, et al.
Pubblicazione: (2024)

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
di: Jason M. Samuels, et al.
Pubblicazione: (2025)

Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
di: Noga C. Minsky, et al.
Pubblicazione: (2025)

Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
di: Søren Seier, et al.
Pubblicazione: (2025)

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
di: Erik Stenberg, et al.
Pubblicazione: (2024)

Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
di: Domenica Rubino, et al.
Pubblicazione: (2024)

Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system
di: Ning Wang, et al.
Pubblicazione: (2026)

Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
di: Alberte Laura Oest Müllertz, et al.
Pubblicazione: (2024)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
di: Alpana P. Shukla, et al.
Pubblicazione: (2025)

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
di: Maria Buur Nordskov Gabe, et al.
Pubblicazione: (2024)

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity
di: Aurélie Phan, et al.
Pubblicazione: (2025)

Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
di: Dario Giugliano, et al.
Pubblicazione: (2024)

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States
di: Xi Tan, et al.
Pubblicazione: (2026)

Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials
di: Beverly G. Tchang, et al.
Pubblicazione: (2025)

Negative familial weight talk and weight bias internalization in a US sample of children and adolescents
di: Katherine M. Rancaño, et al.
Pubblicazione: (2024)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
di: Stergios A. Polyzos, et al.
Pubblicazione: (2026)

An exploration of self‐perception of weight status, weight‐related variables, and preferences for weight management strategies among South Asians in the US
di: Maya E. Joseph, et al.
Pubblicazione: (2025)

Variability in body weight and body composition and cognitive trajectories in older adults in the United States
di: Ashley C. Flores, et al.
Pubblicazione: (2025)

Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
di: Weijun Gu, et al.
Pubblicazione: (2025)

The food insecurity–obesity paradox: a comparison of three obesity measures and sociodemographic disparities in Korean adults
di: Sukyoung Jung, et al.
Pubblicazione: (2025)

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia
di: Hussein ElBadawi, et al.
Pubblicazione: (2025)

The associations of “weekend warrior” and regularly active physical activity with abdominal and general adiposity in US adults
di: Lubi Lei, et al.
Pubblicazione: (2024)

Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights
di: Pavol Kral, et al.
Pubblicazione: (2024)

Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
di: Takefumi Kishimori, et al.
Pubblicazione: (2026)

Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
di: Kevin Cowart, et al.
Pubblicazione: (2025)

How effective are church‐based weight‐loss interventions among Black adults? A systematic review
di: Lovoria B. Williams, et al.
Pubblicazione: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
di: Matthew J. Armstrong, et al.
Pubblicazione: (2024)

Pre‐pregnancy BMI, rate of gestational weight gain, and preterm birth among US Pacific Islander individuals
di: Bohao Wu, et al.
Pubblicazione: (2024)

Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial
di: Melissa‐Rosina Pasqua, et al.
Pubblicazione: (2025)

The impact of lifestyle‐based weight loss in older adults with obesity on muscle and bone health: a balancing act
di: Tiffany M. Cortes, et al.
Pubblicazione: (2025)

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
di: Changyuan Yang, et al.
Pubblicazione: (2026)

Trends in prevalence of health and cardiovascular risk factors based on Life's Essential 8 among US adults, 2007–2020
di: Lixia Zhang, et al.
Pubblicazione: (2025)